Fremanezumab
Fremanezumab
Fremanezumab (pronounced free-man-ez-oo-mab) is a monoclonal antibody medication used for the prevention of migraine in adults. It is marketed under the brand name AJOVY by Teva Pharmaceuticals.
Etymology
The name "Fremanezumab" is derived from the International Nonproprietary Names (INN) system. The "-mab" suffix indicates that it is a monoclonal antibody, while the "Fremane-" prefix is unique to this specific medication.
Mechanism of Action
Fremanezumab works by binding to the calcitonin gene-related peptide (CGRP) or its receptor. CGRP is a neuropeptide that plays a key role in the pathophysiology of migraines. By blocking CGRP, fremanezumab can prevent the onset of migraines.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Migraine: A type of headache characterized by severe pain on one or both sides of the head, nausea, and sometimes visual disturbances.
- Calcitonin gene-related peptide (CGRP): A neuropeptide that plays a key role in the pathophysiology of migraines.
- Teva Pharmaceuticals: An international pharmaceutical company that markets fremanezumab under the brand name AJOVY.
See Also
External links
- Medical encyclopedia article on Fremanezumab
- Wikipedia's article - Fremanezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski